Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

References

• Adikwu MU, Yoshikawa Y, Takada K. (2003). Bioadhesive delivery of metformin using prosopis gum with antidiabetic potential. Biol Pharm Bull 26:662–6
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen EM, Langer R, et al. (2010). Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 197:55–86
   PubMedGoogle Scholar
• Amorim MJ, Ferreira JP. (2001). Microparticles for delivering therapeutic peptides and proteins to the lumen of the small intestine. Eur J Pharm Biopharm 52:39–44
   PubMed Web of Science ®Google Scholar
• Banerjee P, Deb J, Roy A, et al. (2012). Fabrication and development of pectin microsphere of metformin hydrochloride. ISRN Pharm 2012:230621. doi: 10.5402/2012/230621
   PubMedGoogle Scholar
• Basavaraj S, Betageri GV. (2014). Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges. Acta Pharm Sin B 4:3–17
   PubMed Web of Science ®Google Scholar
• Bhavesh D, Chetan G, Bhat KM, et al. (2007). Estimation and pharmacokinetics of metformin in human volunteers. Indian J Pharm Educ Res 41:135–9
   Web of Science ®Google Scholar
• Boldhane SP, Kuchekar BS. (2009). Gastroretentive drug delivery of metformin hydrochloride: formulation and in vitro evaluation using 3(2) full factorial design. Curr Drug Deliv 6:477–85
   PubMedGoogle Scholar
• Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–51
   PubMed Web of Science ®Google Scholar
• Cao J, Liu H, Pan W, et al. (2014). The preparation of the sustained release metformin hydrochloride microcapsules by the Wurster fluidized bed. Pak J Pharm Sci 27:779–84
   PubMed Web of Science ®Google Scholar
• Cetin M, Atila A, Sahin S, et al. (2013). Preparation and characterization of metformin hydrochloride loaded-Eudragit®RSPO and Eudragit®RSPO/PLGA nanoparticles. Pharm Dev Technol 18:570–6
   PubMed Web of Science ®Google Scholar
• Cheng CL, Yu LX, Lee HL, et al. (2004). Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 22:297–304
   PubMed Web of Science ®Google Scholar
• Cho SK, Kim CO, Park ES, et al. (2014). Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol 78:1426–32
   PubMed Web of Science ®Google Scholar
• Choudhury PK, Kar M, Chauhan CS. (2008). Cellulose acetate microspheres as floating depot systems to increase gastric retention of antidiabetic drug: formulation, characterization and in vitro-in vivo evaluation. Drug Dev Ind Pharm 34:349–54
   PubMed Web of Science ®Google Scholar
• Choudhury PK, Kar M. (2009). Controlled release metformin hydrochloride microspheres of ethyl cellulose prepared by different methods and study on the polymer affected parameters. J Microencapsul 26:46–53
   PubMed Web of Science ®Google Scholar
• Corti G, Cirri M, Maestrelli F, et al. (2008). Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-β-cyclodextrin. Eur J Pharm Biopharm 68:303–9
   PubMed Web of Science ®Google Scholar
• Desai D, Wong B, Huang Y, et al. (2014). Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity. J Pharm Sci 103:920–6
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Goodwin PJ, Stambolic V. (2011). Understanding the benefit of metformin use in cancer treatment. BMC Med 9:33
   PubMed Web of Science ®Google Scholar
• Dsilva LC, Palmer J, Sudershan V, et al. (2013). Effect of food on the absorption of metformin from sustained release metformin hydrochloride formulations in healthy Indian volunteers. Asian J Pharm Clin Res 6:95–9
   Google Scholar
• European Pharmacopoeia. (2004). 2005 with Supplements 5.1 and 5.2. 5th ed. Main Volume 5.0. Strasbourg: Council of Europe, 2003 p
   Google Scholar
• Eyal S, Easterling TR, Carr D, et al. (2010). Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 38:833–40
   PubMed Web of Science ®Google Scholar
• Flory J, Haynes K, Leonard CE, et al. (2015). Proton pump inhibitors do not impair the effectiveness of metformin in diabetic patients. Br J Clin Pharmacol 79:330–6
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Metformin hydrochloride tablet. Retrieved March 28, 2015. Available at: http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf, 20.03.2015 [last accessed 11 Sep 2015]
   Google Scholar
• Galindo-Rodriguez SA, Allemann E, Fessi H, et al. (2005). Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 22:419–64
   PubMed Web of Science ®Google Scholar
• Ganjali M, Ganjali H. (2013). Anticancer effect of metformin, an anti diabetic drug, on breast Cancer Cells. J Nov Appl Sci 2:796–801
   Google Scholar
• Garrison KL, Sahin S, Benet LZ. (2015). Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS. J Pharm Sci 104:3229–35
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, et al. (2005). The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487–90
   PubMed Web of Science ®Google Scholar
• Gong L, Goswami S, Giacomini KM, et al. (2012). Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22:820–7
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, et al. (2011). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98
   PubMed Web of Science ®Google Scholar
• Grzybowska M, Bober J, Olszewska M. (2011). Metformin-mechanisms of action and use for the treatment of type 2 diabetes mellitus. Postepy Hig Med Dosw (Online) 65:277–85
   PubMedGoogle Scholar
• Gundogdu N, Cetin M. (2014). Chitosan-poly (lactide-co-glycolide) (CS-PLGA) nanoparticles containing metformin HCl: preparation and in vitro evaluation. Pak J Pharm Sci 27:1923–9
   PubMed Web of Science ®Google Scholar
• Harper W, Clement M, Goldenberg R, et al. (2013). Canadian diabetes association, clinical practice guidelines for the prevention and management of diabetes in Canada: pharmacologic management of type 2 diabetes. Can J Diabetes 37:S61–8
   PubMed Web of Science ®Google Scholar
• Hasan AA, Madkor H, Wageh S. (2013). Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv 20:120–6
   PubMed Web of Science ®Google Scholar
• Haugrud AB, Zhuang Y, Coppock JD, et al. (2014). Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res Treat 147:539–50
   PubMed Web of Science ®Google Scholar
• Idkaidek N, Arafat T, Melhim M, et al. (2011). Metformin IR versus XR pharmacokinetics in humans. J Bioequiv Availab 3:233–5
   Google Scholar
• Idkaidek NM. (2014). Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi Pharm J 22:79–81
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Boyko EJ. (2011). Metformin and colorectal cancer risk in diabetic patients. Diabetes Care 34:2336–7
   PubMed Web of Science ®Google Scholar
• Johansson S, Read J, Oliver S, et al. (2014). Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. Clin Pharmacokinet 53:837–47
   PubMed Web of Science ®Google Scholar
• Jose P, Sundar K, Anjali CH, et al. (2015). Metformin-loaded BSA nanoparticles in cancer therapy: a new perspective for an old antidiabetic drug. Cell Biochem Biophys 71:627–36
   PubMed Web of Science ®Google Scholar
• Jung SH, Chae JW, Song BJ, et al. (2014). Bioequivalence comparison of two formulations of fixed-dose combination glimepiride/metformin (2/500 mg) tablets in healthy volunteers. Iran J Pharm Res 13:365–71
   PubMed Web of Science ®Google Scholar
• Kanazawa I. (2011). A novel attribute of insulin secretion via incretin axis by metformin drug. Int J Endocriol Metab 9:420–1
   Google Scholar
• Kim HG, Hien TT, Han EH, et al. (2011). Metformin inhibits p-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162:1096–108
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Siegel RD. (2012). Metformin and cancer: new applications for an old drug. Med Oncol 29:1314–27
   PubMed Web of Science ®Google Scholar
• Kumar A, Balakrishna T, Rajiv J, et al. (2011). Formulation and evaluation of mucoadhesive microcapsules of metformin HCl with gum karaya. Int J Pharm Pharm Sci 3:150–5
   Google Scholar
• Lekshmi UM, Reddy PN. (2012). Preliminary toxicological report of metformin hydrochloride loaded polymeric nanoparticles. Toxicol Int 19:267–72
   PubMedGoogle Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. (2011). Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34:1431–7
   PubMed Web of Science ®Google Scholar
• Madsen KD, Sander C, Baldursdottir S, et al. (2013). Development of an ex vivo retention model simulating bioadhesion in the oral cavity using human saliva and physiologically relevant irrigation media. Int J Pharm 448:373–81
   PubMed Web of Science ®Google Scholar
• Maida A, Lamont BJ, Cao X, et al. (2011). Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54:339–49
   PubMed Web of Science ®Google Scholar
• Marathe PH, Wen Y, Norton J, et al. (2000). Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 50:325–32
   PubMed Web of Science ®Google Scholar
• Mayer SB, Evans WS, Nestler JE. (2015). Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health (Lond Engl) 11:137–49
   PubMed Web of Science ®Google Scholar
• McCulloch DK. (2015). Metformin in the treatment of adults with type 2 diabetes mellitus. Available from: http://www.uptodate.com/contents/metformin-in-the-treatment-of-adults-with-type-2-diabetes-mellitus# [last accessed 11 Sep 2015]
   Google Scholar
• McCulloch DK, Munshi M. (2014). Treatment of type 2 diabetes mellitus in the older patient, Available from: http://www.uptodate.com/contents/treatment-of-type-2-diabetes-mellitus-in-the-older-patient [last accessed 11 Sep 2015]
   Google Scholar
• Momoh MA, Kenechukwu FC, Attama AA. (2013). Formulation and evaluation of novel solid lipid microparticles as a sustained release system for the delivery of metformin hydrochloride. Drug Deliv 20:102–11
   PubMed Web of Science ®Google Scholar
• Montoya-Eguía SL, Garza-Ocañas L, Badillo-Castañeda CT, et al. (2015). Study among 3 metformin formulations in healthy Mexican volunteers: a single-dose, randomized, open-label, 3-period crossover study. Curr Ther Res 77:18–23
   Web of Science ®Google Scholar
• Morrissey KM, Wen CC, Johns SJ, et al. (2012). The UCSF-FDA transportal: a public drug transporter database. Clin Pharmacol Ther 92:545–6
   PubMed Web of Science ®Google Scholar
• Murphy C, Pillay V, Choonara YE, et al. (2012). Optimization of a dual mechanism gastrofloatable and gastroadhesive delivery system for narrow absorption window drugs. AAPS Pharm Sci Tech 13:1–15
   PubMed Web of Science ®Google Scholar
• Naderpoor N, Shorakae S, Joham A, et al. (2015). Obesity and polycystic ovary syndrome. Minerva Endocrinol 40:37–51
   PubMed Web of Science ®Google Scholar
• Nangia-Makker P, Yu Y, Vasudevan A, et al. (2014). Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 9:e84369
   PubMed Web of Science ®Google Scholar
• Nath B, Nath LK, Mazumdar B, et al. (2009). Design and development of metformin HCl floating microcapsules using two polymers of different permeability characteristics. IJPSN 2:627–37
   Google Scholar
• Orecchioni S, Reggiani F, Talarico G, et al. (2015). The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer 136:E534–44
   PubMed Web of Science ®Google Scholar
• Pandit V, Pai RS, Yadav V, et al. (2013). Pharmacokinetic and pharmacodynamic evaluation of floating microspheres of metformin hydrochloride. Drug Dev Ind Pharm 39:117–27
   PubMed Web of Science ®Google Scholar
• Park SH, Gammon SR, Knippers JD, et al. (2002). Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 92:2475–82
   PubMed Web of Science ®Google Scholar
• Patel HK, Patel PR, Brahmbhatt TJ, et al. (2011). Sustained release microparticles: a review. Am J PharmTech Res 1:108–26
   Google Scholar
• Pavan Kumar BP, Sarath Chandiran IS, Bhavya B, et al. (2011). Microparticulate drug delivery system: a review. Indian J Pharm Sci Res 1:19–37
   Google Scholar
• Pernicova I, Korbonits M. (2014). Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10:143–56
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. (2005). Weight loss in type 2 diabetic patients. Diabetes Care 28:1526–7
   PubMed Web of Science ®Google Scholar
• Raghuwanshi AS, Raghuwanshi AS, Jain UK. (2010). Oral controlled release metformin hydrochloride ion exchange resinate beads. Int J Biomed Adv Res (IJBAR) 1:103–8
   Google Scholar
• Raparla R, Talasila EGKM. (2012). Design and evaluation of floating drug delivery systems of Metformin with natural gums as release retarding polymers. Int J Adv Pharm 1:22–38
   Google Scholar
• Ravi Kumar MN. (2000). Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 3:234–58
   PubMed Web of Science ®Google Scholar
• Ren J, Zhou Y, Zhang G, et al. (2015). Role of age-related decrease of renal organic cation transporter 2 in the effect of atenolol on renal excretion of metformin in rats. Eur J Drug Metab Pharmacokinet 40:349-54
   Google Scholar
• Rizza RA. (2010). Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 59:2697–707
   PubMed Web of Science ®Google Scholar
• Sankhyan A, Pawar PK. (2013). Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization. Daru 21:7
   PubMed Web of Science ®Google Scholar
• Satheesh Madhav NVS, Kala S. (2011). Review on microparticulate drug delivery system. Int J PharmTech Res 3:1242–54
   Google Scholar
• Scheen AJ. (2005). Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 28:601–31
   PubMed Web of Science ®Google Scholar
• Shivhare UD, Darakh V, Mathur VB, et al. (2009). Preparation and evaluation of metformin hydrochloride microcapsules. Res J Pharm Tech (RJPT) 2:559–62
   Google Scholar
• Shugarts S, Benet LZ. (2009). The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039–54
   PubMed Web of Science ®Google Scholar
• Singh MN, Hemant KS, Ram M, et al. (2010). Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci 5:65–77
   PubMedGoogle Scholar
• Snima KS, Jayakumar R, Lakshmanan VK. (2014). In vitro and in vivo biological evaluation of o-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy. Pharm Res 31:3361–70
   PubMed Web of Science ®Google Scholar
• Snima KS, Jayakumar R, Unnikrishnan AG, et al. (2012). O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydr Polym 89:1003–7
   PubMed Web of Science ®Google Scholar
• Spritzer PM, Motta AB, Sir-Petermann T, et al. (2015). Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 40:195–212
   PubMed Web of Science ®Google Scholar
• Su YW, Lin YH, Pai MH, et al. (2014). Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck. PLoS One 9:e96183
   PubMed Web of Science ®Google Scholar
• Sweetman S, ed. (2007). Martindale: the complete drug reference. London: Pharmaceutical Press (Electronic version)
   Google Scholar
• Thulé PM. (2012). Mechanisms of current therapies for diabetes mellitus type 2. Adv Physiol Educ 36:275–83
   PubMed Web of Science ®Google Scholar
• Varde NK, Pack DW. (2004). Microspheres for controlled release drug delivery. Expert Opin Biol Ther 4:35–51
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. (2012). Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122:253–70
   PubMed Web of Science ®Google Scholar
• Wahdan-Alaswad R, Fan Z, Edgerton SM, et al. (2013). Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 12:3759–69
   PubMed Web of Science ®Google Scholar
• Wang LC, Di LQ, Liu R, et al. (2013). Characterizations and microsphere formulation of polysaccharide from the marine clam (Mactra veneriformis). Carbohydr Polym 92:106–13
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2015). Diabetes. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ [last accessed 11 Sep 2015]
   Google Scholar
• Zhang J, Shen C, Wang L, et al. (2014). Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun 452:746–52
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–74
   PubMed Web of Science ®Google Scholar
• Zhou M, Xia L, Wang J. (2007). Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956–62
   PubMed Web of Science ®Google Scholar